Microarray for the Detection of an Angiostatic Tumor Stage of Colorectal Carcinoma

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a microarray-based diagnostic tool for detecting an angiostatic (anti-angiogenic) stage or area in colorectal carcinoma tumors. The microarray uses specific gene probes to assess expression of key molecular markers (notably GBP-1 and antiangiogenic chemokines like CXCL9, CXCL10, and CXCL11) associated with a microenvironment that naturally inhibits new blood vessel formation in tumors. This diagnostic supports personalized treatment approaches by predicting patient response to antiangiogenic and other therapies, and includes related pharmaceutical interventions targeting these markers.

Use CasesContent extracted from patent full text and abstract with AI.

• Diagnosing the angiostatic (anti-angiogenic) stage in colorectal cancer patients using tissue, body fluid, or cell samples.
• Differentiating colorectal carcinoma patients who may respond better to antiangiogenic drugs or immunomodulatory therapy.
• Monitoring colorectal tumor microenvironments to tailor and optimize therapy regimens.
• Guiding drug development by screening for tumors with intrinsic angiostatic activity.
• Predicting response to therapy in other diseases where antiangiogenic mechanisms may play a role, such as breast or lung carcinoma.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables personalized cancer therapy by identifying patients most likely to benefit from specific antiangiogenic or immunomodulatory treatments.
• Improves prognostic accuracy and therapy-stratification in colorectal cancer, potentially leading to better patient outcomes.
• Reduces unnecessary treatment, side effects, and healthcare costs by avoiding ineffective therapies in unsuitable patients.
• May extend to use in other solid tumor types and inflammatory diseases, broadening clinical impact.
• Supports pharmaceutical compositions and drug development targeting key antiangiogenic pathways, offering new therapeutic avenues.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention is directed to a microarray for the detection of an angiostatic tumor stage/tumor area of colorectal carcinoma in a patient, wherein the microarray comprises gene probes capable of specifically hybridizing to predefined nucleic acids. The invention is further directed to an inhibitor or modulator of one or more of these nucleic acids, as well as to a pharmaceutical composition, comrpising those inhibitors or modulators. In a further aspect, the present invention is directed to an ex vivo method for the diagnosis of an angiostatic tumor stage/tumor area in a patient suffering from a colorectal carcinoma. In a further aspect the invention is directed to predict the response of patients with colorectal carcinoma but also other diseases to therapy.